The PRIMA study: a plain language summary on the efficacy and safety of individualized niraparib dosing based on body weight and platelet count
This Plain Language Summary of Publication article from Future Oncology summarises a study called PRIMA. The study looked at whether giving people with advanced ovarian cancer an individualized dose of the medication niraparib, based on how much they weighed and their blood test, would improve patient safety without changing the efficacy (or effectiveness) of the drug.
Visit the Future Medicine using the link to read the article.
The original article on which this summary is based is called ‘Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: results from the PRIMA/ENGOT-OV26/GOG-3012 trial’ and was published in Cancer.
Visit the American Cancer Society Journals using the link to read the article.